On Tuesday, Zydus Lifesciences Ltd. announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.’s AGEN U.S.-based biologics CMC facilities.The acquisition marks Zydus’ strategic investment in U.S.-based biologics manufacturing, thereby adding a sustainable growth driver for the group.Agenus is a clinical-stage immuno-oncology company.Zydus will acquire two biologics manufacturing facilities from Agenus in Emeryvill ...

Shares of Agenus (AGEN) have gained 68.4% over the past four weeks to close the last trading session at $5, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $6.33 indicates a potential upside of 26.6%.The mean estimate comprises three short-term price targets with a standard deviation of $2.08. While the lowest estimate of $4 indicates a 20% decline from the current price level, ...

Agenus (AGEN) Partnerships / Collaborations June 03, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to Agenus Inc. Investor Briefing Call. As a reminder, this conference is being recorded. I will now turn the call over to Zach Arman, Head of Investor Relations. Speaker1 Thank you, operator. Welcome to Agenus' investor briefing call. Earlier today, we issued a press release announcing a strategic collaboration between Agenus and Zydis Life Sciences, which we are here to review in more detail with you ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has been nearly a year and a half since my last Agenus (NASDAQ: AGEN ) article , where I discussed how I believed the market had taken the selling pressure too far for the company’sHe is the leader of the investing group Compounding Healthcare . Featu ...

Momentum investing is essentially an exception to the idea of "buying low and selling high." Investors following this style of investing are usually not interested in betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth potenti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) De ...

Agenus (AGEN) Q1 2025 Earnings Call May 12, 2025 08:30 AM ET Company Participants Zack Armen - Head of IR & Corporate DevelopmentDr. Garo Armen - Chairman & CEORichard Goldberg - Chief Development OfficerChristine Klaskin - Vice President of Finance, Principal Financial Officer & Principal Accounting OfficerSteven O’Day - Chief Medical OfficerJennifer Buell - Chairman & Executive CouncilMayank Mamtani - Senior Managing Director & Group Head of HealthcareMatt Phipps - Group Head - Biotechnology Conference Ca ...

Agenus (AGEN) Q1 2025 Earnings Call May 12, 2025 08:30 AM ET Speaker0 Good morning, and welcome to Agenus, Inc. First Quarter twenty twenty five Earnings Conference Call. Currently, participants are in a listen only mode. A question and answer session will follow the formal remarks. As a reminder, this conference is being recorded. I will now hand the call over to Zach Armen, Head of Investor Relations. Please go ahead. Speaker1 Thank you, operator. Welcome to Adenos' first quarter twenty twenty five financ ...

Exhibit 99.1 Agenus Reports Q1 2025 Financial Results and Key Business Updates May 12, 2025 LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN), a leader in immuno-oncology, today reported financial and operational results for the first quarter of 2025, and shared key clinical and strategic milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) program. "The growing strength of our BOT/BAL data across multiple hard-to-treat cancers reinfo ...

文章核心观点 - Agenus公司股票近一周下跌7.9%，但上一交易日形成锤子线图形态，可能意味着股价找到支撑，有望趋势反转，且华尔街分析师对该公司未来盈利的乐观态度也增强了反转前景 [1][2] 锤子线图相关 - 锤子线图是蜡烛图中流行的价格形态，开盘价和收盘价差距小形成小烛身，当日最低价与开盘价或收盘价差距大形成长下影线，下影线长度至少是实体的两倍，形似“锤子” [3] - 下跌趋势中，锤子线图出现意味着空头可能失去对价格的控制，多头成功阻止价格进一步下跌，预示潜在趋势反转，可出现在任何时间框架，供短期和长期投资者使用 [4] - 锤子线图有局限性，其强度取决于在图表上的位置，应与其他看涨指标结合使用 [5] Agenus公司趋势反转因素 - Agenus公司近期盈利预测修正呈上升趋势，是基本面的看涨指标，因实证研究表明盈利预测修正趋势与短期股价走势密切相关 [6] - 过去30天，当前年度的共识每股收益预期增长7.4%，表明覆盖该公司的华尔街分析师大多认同其盈利可能好于此前预测 [7] - Agenus公司目前Zacks排名为2（买入），处于基于盈利预测修正趋势和每股收益意外情况排名的4000多只股票的前20%，通常排名1或2的股票表现优于市场，该排名是潜在趋势反转的更确凿迹象 [8]